Genovis AB (OSTO:GENO) Total Liabilities: kr104.6 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:GENO Genovis AB OSTO:GENO
93 GF Score
Price kr20.00
GF Value kr28.83
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Genovis AB Total Liabilities?

Genovis AB OSTO:GENO +5.71% 93 Total Liabilities is kr104.6 Mil as of Mar. 2026. GuruFocus rates OSTO:GENO with a GF Score™ of 93/100 and a GF Value™ of kr28.83 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Genovis AB's Total Liabilities for the quarter that ended in Mar. 2026 was kr104.6 Mil.

Genovis AB's quarterly Total Liabilities increased from Sep. 2025 (kr102.46 Mil) to Dec. 2025 (kr106.41 Mil) but then declined from Dec. 2025 (kr106.41 Mil) to Mar. 2026 (kr104.58 Mil).

Genovis AB's annual Total Liabilities increased from Dec. 2023 (kr98.05 Mil) to Dec. 2024 (kr99.44 Mil) and increased from Dec. 2024 (kr99.44 Mil) to Dec. 2025 (kr106.41 Mil).

Genovis AB Total Liabilities Historical Data

* Premium members only.

The historical data trend for Genovis AB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovis AB Total Liabilities Chart

Genovis AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.76 24.87 98.05 99.44 106.41

Genovis AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.37 95.26 102.46 106.41 104.58
OSTO:GENO
93GF Score
Genovis AB OSTO:GENO
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovis AB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Genovis AB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.071+(66.757+11.582
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=106.4

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=377.934-271.524
=106.4

Genovis AB's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=27.833+(0+76.745
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=104.6

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=381.941-277.363
=104.6

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr104.6 Mil mean?
Genovis AB (OSTO:GENO) has a Total Liabilities of kr104.6 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genovis AB and its competitors.
Is Genovis AB's Total Liabilities too high?
Genovis AB's current Total Liabilities is kr104.6 Mil. Overall, Genovis AB has a GF Score™ of 93/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genovis AB's Total Liabilities compare to VRTX and REGN?
Genovis AB's Total Liabilities of kr104.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Genovis AB and its competitors. Genovis AB's current Total Liabilities is kr104.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovis AB stock overvalued right now?
Based on GuruFocus' analysis, Genovis AB (OSTO:GENO) is currently considered Significantly Undervalued. The stock's GF Value™ is kr28.83, compared to a current price of kr20.00 — trading 30.6% below its estimated fair value. The current Total Liabilities is kr104.6 Mil. Genovis AB's overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Genovis AB (OSTO:GENO), the current Total Liabilities is kr104.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovis AB (OSTO:GENO) Overvalued in 2026?

Based on GuruFocus' analysis, Genovis AB stock appears to be undervalued. The current stock price of kr20.00 is trading 30.6% below its estimated GF Value™ of kr28.83. GuruFocus considers Genovis AB to be Significantly Undervalued.

Key valuation signals for OSTO:GENO:

  • Total Liabilities: kr104.6 Mil
  • GF Value™: kr28.83 vs. price of kr20.00 (30.6% below fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the OSTO:GENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genovis AB Business Description

Address Kavlinge, Box 4, Lund, SWE, SE-24421
Genovis AB offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Its enzyme products, known as SmartEnzymes, are used by scientists all over the world, and the product formats facilitate the development and quality control of biological drugs. Its products include Enzyme and Antibodies. Geographically, it operates in Sweden and Rest of the world.
93GF Score

Get the complete analysis for OSTO:GENO

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.00
Price
kr28.83
GF Value